UNITED
STATES
 SECURITIES
AND EXCHANGE COMMISSION
 Washington,
D.C. 20549
 
 FORM
10-Q
  (Mark
One)
 x QUARTERLY REPORT
UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 For the
quarterly period ended December 31, 2008
 
 o TRANSITION REPORT
UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
 
 For the
period from October 1st 2008 to
December 31st
2008
 
 000-31469
 (Commission
file number)
 
 Medical International
Technology, Inc.
 (Exact
name of small business issuer as specified in its charter)
  Colorado
                        
                        84-1509950(State
      or other jurisdiction
                          of
      incorporation or organization)
                        
                        (IRS
      Employer Identification
No.)
  1872
Beaulac
 Ville
Saint-Laurent
 Montréal, Québec, Canada H4R
2E7
 (Address
of principal executive offices)
 
 (514)
339-9355
 (Issuer's
telephone number)
 
 
 (Former
name, former address and former fiscal year, if changed since last
report)
 
 Check
whether the issuer (1) filed all reports required to be filed by Section 13 or
15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. Yes x No o
  Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company.  See the definitions of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act.
  Large accelerated filer £                                                                                                Accelerated
filer £
  Non-accelerated filer £                                                                                                 
Smaller reporting company £
 (Do
not check is a smaller reporting company)
  Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes o No x
 
 The
number of shares outstanding of each of the issuer's classes of common equity as
of December
31, 2008: 51,058,663 shares of common stock
 
 Transitional
Small Business Disclosure Format (check one): Yes o No x











PART
      I.    FINANCIAL INFORMATIONItem
      1.      Consolidated Financial
      Statements
                      3Consolidated
      Balance Sheet
                      3Consolidated
      Statements of Operations,
                      5Consolidated
      Statements of Cash Flows
                      6Consolidated
      Statements of Comprehensive Loss
                      7Consolidated
      Statement of Stockholders’ (Deficit)
                      8Notes
      to Unaudited Consolidated Financial Statements
                      9Item
      2.       Management's Discussion and
      Analysis of Financial
      Condition and Plan of Operations
                      13Item
      3.       Quantitative and Qualitative
      Disclosures About Market Risk
                      15Item
      4.       Controls and
      Procedures
                      15Part
      II. OTHER INFORMATIONItem
      1        Legal
      Proceedings
                      16Item
      1A.    Risk Factors
                      16Item
      2.       Unregistered Sales of Equity
      Securities and Use of Proceeds
                      19Item
      3.       Defaults upon Senior
      Securities
                      16Item
      4.       Submission of Matters to a
      Vote of Security Holders
                      16Item
      5.       Other Information
                      16Item
      6.       Exhibits and Reports on Form
      8-K
                      16SIGNATURES
                      17






-2-




Item
1. Financial Information






Medical
      International Technology, Inc.
            Quarterly
      Financial Report






CONSOLIDATED BALANCE SHEETDecember 31, 2008
                                                  
                                                  
                                                  September 30, 2008(Unaudited)
                                                  
                                                  
                                                  (Audited)AssetsCurrent AssetsCash
      and cash equivalents
                                                  
                                                  $
                                                  11,704
                                                  
                                                  
                                                  $
                                                  94,834Accounts
      receivable
                                                  
                                                  
                                                  1,868
                                                  
                                                  
                                                  
                                                  ---Inventories
                                                  
                                                  
                                                  164,339
                                                  
                                                  
                                                  
                                                  169,459Prepaid
      expenses
                                                  
                                                  
                                                  2,735
                                                  
                                                  
                                                  
                                                  3,565Total
      Current Assets
                                                  
                                                  
                                                  180,646
                                                  
                                                  
                                                  
                                                  267,858Property
      and EquipmentTooling
      and machinery
                                                  
                                                  
                                                  229,823
                                                  
                                                  
                                                  
                                                  229,823Furniture
      and office equipment
                                                  
                                                  
                                                  133,014
                                                  
                                                  
                                                  
                                                  133,014Leasehold
      improvements
                                                  
                                                  
                                                  22,163
                                                  
                                                  
                                                  
                                                  22,163385,000
                                                  
                                                  
                                                  
                                                  385,000Less
      accumulated depreciation
                                                  
                                                  
                                                  (312,841
                                                  )
                                                  
                                                  
                                                  (299,500
                                                  )72,159
                                                  
                                                  
                                                  
                                                  85,500Other AssetsPatents
      (net accumulated amortization of $1,514 and $1,398)
                                                  
                                                  
                                                  515
                                                  
                                                  
                                                  
                                                  632Total
      Assets
                                                  
                                                  $
                                                  253,320
                                                  
                                                  
                                                  $
                                                  353,990







The
accompanying notes are an integral part of these consolidated financial
statements
 -3-
 
 Medical
      International Technology, Inc.
                Quarterly
      Financial Report
  CONSOLIDATED BALANCE SHEETDecember
      31
                            2008
                          
                          
                          September
      30
                            2008(Unaudited)
                          
                          
                          (Audited)Liabilities
      and Stockholders' Equity (Deficit)Current
      LiabilitiesDeferred income
                          
                          $
                          1,336,165
                          
                          
                          $
                          1,353,782Accounts payable and accrued expenses
                          
                          
                          228,506
                          
                          
                          
                          90,245Amounts due to related parties
                          
                          
                          1,695,767
                          
                          
                          
                          1,524,321Current portion of long-term debts
                          
                          
                          7,740
                          
                          
                          
                          8,2373,268,178
                          
                          
                          
                          2,976,585Long-Term Debts
                          
                          
                          2,265
                          
                          
                          
                          6,860Total
      Liabilities
                          
                          
                          3,270,443
                          
                          
                          
                          2,983,445Stockholders'
      Equity (Deficit)Preferred
      stock, $.0001 par value; 3,000,000 shares authorized;None
      issued and outstanding as of December 31, 2007Common
      stock, $.0001 par value; 100,000,000 shares authorized;51,058,663
      and 27,058,663 shares issued andOutstanding,
      respectively
                          
                          
                          5,106
                          
                          
                          
                          2,706Additional
      paid-in capital
                          
                          
                          6,825,939
                          
                          
                          
                          6,804,339Deficit
                          
                          
                          (9,913,815
                          )
                          
                          
                          (9,333,413
                          )Other
      comprehensive income (loss)
                          
                          
                          65,647
                          
                          
                          
                          (103,087
                          )Total
      Stockholders' Equity (Deficit)
                          
                          
                          (3,017,123
                          )
                          
                          
                          (2,629,455
                          )Total
      Liabilities and Stockholders' Equity (Deficit)
                          
                          
                          253,320
                          
                          
                          $
                          353,990


The
accompanying notes are an integral part of these consolidated financial
statements
 -4-
 
  Medical
      International Technology, Inc.
                  Quarterly
      Financial Report


CONSOLIDATED STATEMENTS OF
      OPERATIONSFor the Three-Month
      Period Ended December 31,2008
                      
                      
                      2007(Unaudited)
                      
                      
                      (Unaudited)Sales
                      
                      $
                      70,915
                      
                      
                      $
                      118,592Cost
      of sales
                      
                      
                      (51,610
                      )
                      
                      
                      (51,399
                      )Gross
      profit
                      
                      
                      19,305
                      
                      
                      
                      67,193Research
      and development costs
                      
                      
                      (450,000
                      )
                      
                      
                      (55,064
                      )Selling,
      general, and administrative expenses
                      
                      
                      (150,378
                      )
                      
                      
                      (172,059
                      )(600,378
                      )
                      
                      
                      (227,123
                      )Net
      loss from operations
                      
                      
                      (581,073
                      )
                      
                      
                      (159,930
                      )Other
      Income (Expense)Interest
      income
                      
                      
                      1,312
                      
                      
                      
                      768Interest
      expense
                      
                      
                      (641
                      )
                      
                      
                      (14,112
                      )671
                      
                      
                      
                      (13,344
                      )Net
      loss
                      
                      $
                      (580,402
                      )
                      
                      $
                      (173,274
                      )Basic
      (loss) per share
                      
                      $
                      (0.016
                      )
                      
                      $
                      (0.006
                      )Basic
      weighted average shares outstanding
                      
                      
                      37,232,576
                      
                      
                      
                      27,058,663






The
accompanying notes are an integral part of these consolidated financial
statements
 -5-




Medical
      International Technology, Inc.
              Quarterly
      Financial Report




CONSOLIDATED STATEMENTS OF CASH
      FLOWSThree-Month
      Period EndedDecember
      31,2008
                                            
                                            
                                            2007Cash
      Flows from Operating Activities
                                            
                                            (Unaudited)
                                            
                                            
                                            (Unaudited)Net
      Loss
                                            
                                            $
                                            (580,402
                                            )
                                            
                                            $
                                            (173,274
                                            )Adjustments
      to reconcile net loss to net cashUsed in operating activities:Depreciation
      and amortization expense
                                            
                                            
                                            13,458
                                            
                                            
                                            
                                            13,701Common
      stock issued for consulting and legal services
                                            
                                            
                                            4,000
                                            
                                            
                                            
                                            -(Increase)
      decrease in Assets(Increase)
      decrease in accounts receivable
                                            
                                            
                                            (1,868
                                            )
                                            
                                            
                                            2,014(Increase)
      decrease in inventories
                                            
                                            
                                            5,120
                                            
                                            
                                            
                                            14,752(Increase)
      decrease in research tax credit receivable
                                            
                                            
                                            -
                                            
                                            
                                            
                                            11,029(Increase)
      decrease in prepaid expenses
                                            
                                            
                                            830
                                            
                                            
                                            
                                            (5,744
                                            )Increase
      (decrease) in LiabilitiesIncrease
      (decrease) in deferred income
                                            
                                            
                                            (17,617
                                            )
                                            
                                            
                                            1,292,476Increase
      (decrease) in accounts payable and accrued expenses
                                            
                                            
                                            138,261
                                            
                                            
                                            
                                            (160,802
                                            )Net
      Cash Used in Operating Activities
                                            
                                            
                                            (438,218
                                            )
                                            
                                            
                                            994,152Cash
      Flows from Financing ActivitiesGross
      proceeds from private offering
                                            
                                            
                                            -
                                            
                                            
                                            
                                            -Reduction
      in amounts due to related parties
                                            
                                            
                                            191,446
                                            
                                            
                                            
                                            (844
                                            )Principal
      reduction on small business loan
                                            
                                            
                                            (5,092
                                            )
                                            
                                            
                                            -259,519Net
      Cash Provided by Financing Activities
                                            
                                            
                                            186,354
                                            
                                            
                                            
                                            (260,363
                                            )Effect
      of exchange rates on cash
                                            
                                            
                                            168,734
                                            
                                            
                                            
                                            (109,872
                                            )Net
      Increase (decrease) in Cash and Cash Equivalents
                                            
                                            
                                            (83,130
                                            )
                                            
                                            
                                            (169,085
                                            )Beginning
      Balance - Cash and Cash Equivalents
                                            
                                            
                                            94,834
                                            
                                            
                                            
                                            187,536Ending
      Balance - Cash and Cash Equivalents
                                            
                                            $
                                            11,704
                                            
                                            
                                            $
                                            18,450Supplemental
      Information:Cash Paid
      For:Interest
      Expenses
                                            
                                            $
                                            641
                                            
                                            
                                            
                                            14,112Income
      Taxes
                                            
                                            $
                                            -
                                            
                                            
                                            $
                                            -Non-cash
      transactions:Related party payables
      settle by common stock
                                            
                                            $
                                            20,000
                                            
                                            
                                            $
                                            -






The
accompanying notes are an integral part of these consolidated financial
statements
 -6-






Medical
      International Technology, Inc.
              Quarterly
      Financial Report




CONSOLIDATED STATEMENTS OF COMPREHENSIVE
      LOSSFirst
      quarter ending
                                                                  December
      31,
                                                                  2008
                                                                
                                                                
                                                                First
      quarter ending
                                                                  December
      31,
                                                                  2007Net
      loss
                                                                
                                                                $
                                                                (576,402
                                                                )
                                                                
                                                                $
                                                                (173,274
                                                                )Other
      comprehensive income (loss)Foreign
      currency translation adjustment
                                                                
                                                                
                                                                168,734
                                                                
                                                                
                                                                
                                                                (109,872
                                                                )Net comprehensive income (loss)
                                                                
                                                                $
                                                                (407,668
                                                                )
                                                                
                                                                $
                                                                (283,146
                                                                )






The
accompanying notes are an integral part of these consolidated financial
statements
 -7-




Medical
      International Technology, Inc.
              Quarterly
      Financial Report




ReportCONSOLIDATED STATEMENT OF STOCKHOLDERS’
      (DEFICIT)Common Stock
                                                                                            
                                                                                            
                                                                                            Additional Paid inShares
                                                                                            
                                                                                            
                                                                                            Amount
                                                                                            
                                                                                            
                                                                                            Capital
                                                                                            
                                                                                            
                                                                                            DeficitBalance
      – September 30, 2008
                                                                                            
                                                                                            
                                                                                            27,058,663
                                                                                            
                                                                                            
                                                                                            $
                                                                                            2706
                                                                                            
                                                                                            
                                                                                            $
                                                                                            6,804,339
                                                                                            
                                                                                            
                                                                                            $
                                                                                            (9,333,413
                                                                                            )Shares
      issued for debts
                                                                                            
                                                                                            
                                                                                            20,000,000
                                                                                            
                                                                                            
                                                                                            
                                                                                            2,000
                                                                                            
                                                                                            
                                                                                            
                                                                                            18,000
                                                                                            
                                                                                            
                                                                                            
                                                                                            -Shares
      issued for services
                                                                                            
                                                                                            
                                                                                            4,000,000
                                                                                            
                                                                                            
                                                                                            
                                                                                            400
                                                                                            
                                                                                            
                                                                                            
                                                                                            3,600
                                                                                            
                                                                                            
                                                                                            
                                                                                            -Net loss for the period ended
      December 31, 2008
                                                                                            
                                                                                            
                                                                                            -
                                                                                            
                                                                                            
                                                                                            
                                                                                            -
                                                                                            
                                                                                            
                                                                                            
                                                                                            -
                                                                                            
                                                                                            
                                                                                            
                                                                                            (580,402
                                                                                            )Balance
      – December 31, 2008
                                                                                            
                                                                                            
                                                                                            51,058,663
                                                                                            
                                                                                            
                                                                                            $
                                                                                            5,106
                                                                                            
                                                                                            
                                                                                            $
                                                                                            6825,939
                                                                                            
                                                                                            
                                                                                            $
                                                                                            (9,913,815
                                                                                            )






The
accompanying notes are an integral part of these consolidated financial
statements
 -8-




Medical
      International Technology, Inc.
                  Quarterly
      Financial Report
 Notes
to Financial Statements
 
 (Unaudited)




Note
1 – Basis of Presentation
  Interim
Financial Statements
 The
accompanying unaudited condensed consolidated financial statements of Medical
International Technology, Inc. and its subsidiary (collectively referred to as
the “Company”) have been prepared in accordance with accounting principles
generally accepted in the United States of America, pursuant to the rules and
regulations of the Securities and Exchange Commission.  All
significant intercompany balances and transactions have been
eliminated.  These financial statements do not include all information
and notes required by accounting principles generally accepted in the United
States of America for complete financial statements.  It is
recommended that these interim unaudited condensed consolidated financial
statements be read in conjunction with the consolidated financial statements and
notes thereto included in the Company's Annual Report on Form 10-K for the
fiscal year ended September 30, 2008.
  In the
opinion of management, all adjustments (consisting only of normal recurring
accruals) considered necessary for a fair presentation have been
included.  Operating results for the three month period ended December
31, 2008 are not necessarily indicative of the results which may be expected for
any other interim periods or for the year ending September 30, 2009. The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from these
estimates.
  Note
2 – Unearned income
 
 On
November 1st, 2007,
the Company received a Non-Refundable deposit of $1,300,000 for the worldwide
rights to market and sells all Medical International Technology Inc.’s present
and future Needle-Free Jet-Injectors for the human and animal markets. This
deposit is part of an agreement under negotiation, and will be disclosed when
finalized, which the Company expects to occur in fiscal 2009.  The
Company has recorded the deposit as unearned income until such time as a final
agreement is reached, at which time the deposit will be earned as income over
the estimated contractual life of the final agreement.
 
 Note
3 –
Inventories
  Inventories
at December 31, 2008and September
30, 2008 consist of the following:
  December
      31,
                                2008
                              
                              
                              September
      30,
                                2008Raw
      materials
                              
                              $
                              128,181
                              
                              
                              $
                              139,604Work
      in process
                              
                              
                              31,560
                              
                              
                              
                              23,863Finished
      goods
                              
                              
                              4,598
                              
                              
                              
                              5,992Total
                              
                              $
                              164,339
                              
                              
                              $
                              169,459
   -9-
  Medical
      International Technology, Inc.
                    Quarterly
      Financial Report
 Notes
to Financial Statements
 
 (Unaudited)
 Note
4 – Research Credit Receivable
  Research
and development costs are charged to operations when incurred. For its research
efforts in Canada, the Company receives a cash payment from the Canadian
Government based upon the amount actually incurred. The Company nets the credit
against related costs charged to operations. Research and development expenses
are as follows:
  December
      31,
                        2008
                      
                      
                      September
      30,2008R&D
      Costs
                      
                      $
                      450,000
                      
                      
                      $
                      1,802,857Less
      Credit
                      
                      
                      -
                      
                      
                      
                      (3,158
                      )$
                      450,000
                      
                      
                      $
                      1,802,085
  Note
5 – Property and Equipment
  The cost
of property and equipment is depreciated over the estimated useful lives of the
related assets, which range from 5 to 7 years. Depreciation is computed on the
straight-line method for financial reporting purposes and on the declining
balance method for income tax reporting purposes. Depreciation expense for the
three-months ended December 31, 2008and 2007 were $13,341, and $13,584,
respectively.
  Note
6 –
Intangible Assets
  As of
December 31, 2008 the Company has net intangible assets totaling $ 515.
Amortization expenses for the three-months ended December 31, 2008 and 2007 were
$116, and $116, respectively.  Intangible assets consist of the
following:
  Gross
                          Intangible
                          Assets
                        
                        
                        AccumulatedAmortization
                        
                        
                        Net
                          Intangible
                          Assets
                        
                        Weighted
                          Average
                          Life
                          (Years)Patents
                        
                        $
                        2,030
                        
                        
                        $
                        1,515
                        
                        
                        $
                        515
                        
                        8.5
      through
16
  Note
7 –
Related Party Transactions
 
 Related
party balances consist of the following at December 31, 2008 and September 30,
2008:
  December
      31,
                              2008
                            
                            
                            September
      30,
                              2008Payable
      to Idee International R&D, Inc.
                            
                            $
                            1,695,767
                            
                            
                            $
                            1,480,378Payable
      to 2849-674 Canada, Inc.
                            
                            
                            -
                            
                            
                            
                            34,637Payable
      to 9117-2221 Quebec Inc.
                            
                            
                            -
                            
                            
                            
                            9,306$
                            1,695,767
                            
                            
                            $
                            1,524,321
  
 -10-
   Medical
      International Technology, Inc.
                    Quarterly
      Financial Report
 Notes
to Financial Statements
 
 (Unaudited)
 
 Common
Stock
 From time
to time, the Company will issue common stock for services rendered, debt
reductions or as part of private placement offerings.  For the quarter
ended December 31, 2008, the Company issued 20,000,000 shares of common stock to
a related party for payment of outstanding payables of $20,000.  In
addition, the Company issued 2,000,000 shares of common stock to the Company’s
Chief Executive Officer and 2,000,000 shares to the Company’s Chief Financial
Officer for services rendered to the Company.  The value of those
services was $4,000.
  Preferred
Stock
  As of
December 31, 2008, there was no preferred stock outstanding. Dividend features
and voting rights are at the discretion of the Board of Directors without the
requirement of shareholder approval.
  Outstanding
Options
  As of
December 31, 2008, there were no outstanding stock options.
  Outstanding
Warrants
  As of
December 31, 2008, there were no outstanding warrants.
  Note
9 – Notes Payable
 
 Long-term
debt consists of the following at December 31, 2008 and September 30,
2008:
  December
      31,
                          2008
                        
                        
                        September
      30,
                          2008Note
      payable to a bank, bearing interest at prime plus 2.5%secured by
      equipment, due July 21, 2010.
                        
                        $
                        10,005
                        
                        
                        $
                        15,097Current
      portion of long-term debt
                        
                        
                        7,740
                        
                        
                        
                        (8,237
                        )Long-term
      debt
                        
                        $
                        2,265
                        
                        
                        $
                        6,860Scheduled
      maturities of long-term debt are as follows:December 31,
    2009
                        
                        
                        7,740December 31,
    2010
                        
                        
                        2,265
   
 -11-
  Medical
      International Technology, Inc.
                  Quarterly
      Financial Report
 Notes
to Financial Statements
 
 (Unaudited)
  
 Note
10 – Contingencies
  Legal
Proceedings
  From time
to time, the Company is named in legal actions in the normal course of business.
In the opinion of management, the outcome of these matters, if any, will not
have a material impact on the financial condition or results of operations of
the Company.
  
  -12-
 Medical
International Technology, Inc.
 
 
 Item
2.   Management's Discussion and Analysis of Financial Condition
and Plan of Operations
 
 All
statements that are included in this Quarterly Report, other than statements of
historical fact, are forward looking statements.  Although management
believes that the expectations reflected in these forward looking statements are
reasonable, it can give no assurance that such expectations will prove to have
been correct.
  Financial
Summary
  Results of Operations for
the Three-Months ended December 31, 2008 and 2007
  For the
three-month period ended December 31, 2008, the Company experienced a net loss
from operations of  $577,073 which was primarily due to research and
development costs of  $450,000 and selling, general and administrative
expenses of  $146,378. Gross profits for the period were
$19,305.
 
 For the
three-month period ended December 31, 2007, the Company’s net loss from
operations was $159,930, which was primarily due to research and development
costs of  $55,064 and selling, general and administrative expenses of
$172,059. Gross profits for this period were $67,193.
 
 For the
three-months ended December 31, 2008, the Company experienced an increase in
sales compared to sales for the same period last year. Sales for the three-month
period ending December 31, 2008 were $70,915 compared to sales of $118,592 for
the same period last year. Gross profits for the period ending December 31, 2008
represented 27% of sales, where gross profits for the same period last year
represented 56% of sales.
  Liquidity and Capital
Resources
 
 For the
three-month period ending December 31, 2008, the Company’s cash position
decreased $83,130. Net cash used in operating activities was $438,218; financing
activities provided $186,354; and the effect of exchange rates on cash provided
$168,734
  For the
three-month period ending December 31, 2007, the Company’s cash position
decreased $169,085. Net cash used in operating activities was $994,152;
financing activities provided $0; and the effect of exchange rates on cash
provided $109,872.
 
 Management
Plan of Operations
 
 Medical
International Technology, Inc. (“MIT”) is engaged in the business of research,
development, marketing and sales of needle-free jet injector technology and
products for humans and animals, for single and mass injections.
 
 We
continue to market our product in all available markets, seek regulatory
approvals to expand those market opportunities and improve our products for
application to new markets.
 
 Medical
International Technology, Inc. has recently completed several rounds of
financing resulting in net proceeds to the company of approximately $1,287,520
and continues efforts to secure additional funding to support and expand
operations.   Funds from these sales of our common stock are
being used to fund continued operations, develop and seek regulatory approvals
for our products and market those products worldwide.
 
 Medical
International Technology, Inc. will continue to seek additional funding to
expand operations and develop sales revenue to a volume sufficient to sustain
operations.
  -13-
   Medical
International Technology, Inc.
 
 Product
Development
 
 Medical
International Technologies has filed for FDA approval for its needle-free
injector – the MED-JET, designed specifically for human mass inoculations. The
MED-JET is capable of delivering many types of medications such as vaccines,
insulin and other types of injectables. Its low-pressure technology offers an
advantage to alternative high pressure systems that can cause blowbacks and
expose medical workers and patients alike to microscopic traces of
blood.
 
 According
to the International Sharps Injury Prevention Society (http://www.isips.org), it
has been estimated that one out of every seven workers is accidentally stuck by
a contaminated sharp point each and every year. The Center for Disease Control
(CDC: http://www.cdc.gov/niosh/2000-108.html#5) estimates that there are 600,000
to 800,000 needle stick injuries per year in the U.S. alone, and many are not
reported. More than 20 types of infectious agents have been transmitted through
needlesticks, including hepatitis B and C, tuberculosis, syphilis, malaria,
herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The
MED-JET will eliminate this risk to our health care professionals and create a
safer workplace. Other advantages include its light weight (0.5 kg) and an
excellent medication absorption rate. Additionally, the system has the ability
to increase or decrease the volume and pressure of injection. This technology is
unique to MIT’s MED-JET MBX Injector. The system is designed to inject up to 600
individuals an hour.
 
 The
approval process can be expensive and may take extended period of time. There
can be no assurance that this system will receive approval from the FDA or if
approved gain broad acceptance by the medical community or individual
patients.
 
 On
December 15, 2005, Medical International Technologies, Inc announced that it has
received full certification granted under the International Organization for
Standardization, as well as the Canadian Medical Device Conformity Assessment
System, for devices to be licensed by HEALTH CANADA. These certifications allow
MIT to market the Med-Jet Needle-Free Injector for human use in all countries
other than the U.S., at this point. The Med-Jet injector has been submitted for
FDA approval which, if accepted, will allow MIT to sell the Med-Jet in the
United States, making it a truly worldwide system.
 
 MIT's
Needle-Free Injection System, designed specifically to allow fast, accurate and
safe injections, is rapidly moving toward establishing itself as a valuable
instrument in the fight against disease in both humans and animals. Spurred on
by growing fears of a world wide epidemic that could match or even exceed the
deadly flu pandemic of 1918, which killed millions of people, the MIT team is
focusing its efforts to make its Needle-Free Injection System available to the
world.
 
 Now that
MIT is able to sell its Med-Jet in all countries, other than the U.S., it is
working to complete two FDA filings. The first of these will be for use of the
Med-Jet for injecting anesthesia in a variety of situations. The second, and
most significant in light of the news coming out of Asia concerning the spread
of Influenza A (H5N1) to humans, will be the Med-Jet-H, for mass vaccination in
case of a pandemic, such as Avian Influenza, Polio, Tuberculosis, Malaria or
HIV.
 
 MIT is
also pursuing increasing interest in its Agro-Jet needle-free injector. Having
the same benefits as Med-Jet, Agro-Jet will become a valuable instrument in the
fight against Avian Flu via its ability to mass inoculate animals at over 1000
injections per hour.
 
 On
December 22, 2005 we announced that as part of its continuing restructuring
program MIT is forming two divisions. The Human Medical Technology Division will
focus on the development, production, marketing and sale of needle-free
injectors and other medical technologies for humans. The Animal Medical
Technology Division will deal with all aspects of the development, production,
marketing and sale of the needle-free injectors and other technologies for
animal applications worldwide.
 
 On
December 19, 2005 the Board of MIT adopted a resolution stating "MIT will
acquire all of the issued and outstanding shares of 9139-2449 Quebec Inc
operating under the name “Scanview” for 2,500,000 restricted common shares of
MIT". No shares have been issued and the final terms are pending acceptance by
the shareholders of Scanview.
 
 On
December 22, 2005 we announced that MIT would proceed with the ScanView
acquisition. Scanview is a portable ultrasound technology and manufacturing
company based in Montreal, Quebec, Canada. ScanView was formed in 2003 to
develop, manufacture and market different models of Real Time Ultrasound
Scanners, for Animal and Human applications.
  -14-
   Medical
International Technology, Inc.
 
 
 ScanView
has a unique, portable and battery operated ultrasound diagnostic medical
device, using a variety of probes for pathological and physiological evaluation
of organs such as the heart, kidneys, liver, thyroid, uterus and ovaries. They
serve equally well to detect kidney stones, diagnose pregnancy, visualize
follicle development and carry out all other normal ultrasound diagnostic
procedures.
  Forward-Looking
Statements
 
 Certain
statements concerning the Company's plans and intentions included herein may
constitute forward-looking statements for purposes of the Securities Litigation
Reform Act of 1995 for which the Company claims a safe harbor under that Act.
There are a number of factors that may affect the future results of the Company,
including, but not limited to, (a) the ability of the company to obtain
additional funding for operations, (b) the continued availability of management
to develop the business plan and (c) successful development and market
acceptance of the company’s products. This periodic report may contain both
historical facts and forward-looking statements. Any forward-looking statements
involve risks and uncertainties, including, but not limited to, those mentioned
above. Moreover, future revenue and margin trends cannot be reliably
predicted.
 
 Item
3.   Quantitative and Qualitative Disclosures About Market
Risk
 
 Not required for Smaller Reporting
Companies.
 
 Item
4.   Controls and Procedures
 
 Evaluation of our Disclosure
Controls
 As of the
end of the period covered by this Quarterly Report on Form 10-Q, our principal
executive officer and principal financial officer have evaluated the
effectiveness of our “disclosure controls and procedures” (“Disclosure
Controls”). Disclosure Controls, as defined in Rule 13a-15(e) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), are procedures that are
designed with the objective of ensuring that information required to be
disclosed in our reports filed under the Exchange Act, such as this Quarterly
Report, is recorded, processed, summarized and reported within the time periods
specified in the Securities and Exchange Commission’s rules and forms.
Disclosure Controls are also designed with the objective of ensuring that such
information is accumulated and communicated to our management, including the CEO
and CFO, as appropriate to allow timely decisions regarding required disclosure.
Our management, including the CEO and CFO, does not expect that our Disclosure
Controls will prevent all error and all fraud. A control system, no matter how
well conceived and operated, can provide only reasonable, not absolute,
assurance that the objectives of the control system are met. Further, the design
of a control system must reflect the fact that there are resource constraints,
and the benefits of controls must be considered relative to their costs. Because
of the inherent limitations in all control systems, no evaluation of controls
can provide absolute assurance that all control issues and instances of fraud,
if any, within the company have been detected. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that
breakdowns can occur because of simple error or mistake. The design of any
system of controls also is based in part upon certain assumptions about the
likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future
conditions.
 
 Based
upon their controls evaluation, our CEO and CFO have concluded that our
Disclosure Controls are effective at a reasonable assurance level.
  Changes
in internal control over financial reporting
 There
have been no changes in our internal controls over financial reporting during
our third fiscal quarter that have materially affected, or are reasonably likely
to materially affect, our internal control over financial
reporting.
    -15-
 
 
 PART
II OTHER INFORMATION
 
 
 Item
1.   Legal Proceedings
  From time
to time, the Company is named in legal actions in the normal course of business.
In the opinion of management, the outcome of these matters, if any, will not
have a material impact on the financial condition or results of operations of
the Company.
  Item
1A. Risk Factors
 
 Not required for Smaller Reporting
Companies.
 
 Item
2.   Unregistered Sales of Equity Securities and Use of
Proceeds
 
 None.
 
 Item
3.   Defaults upon Senior Securities
 
 None
 
 Item
4.   Submission of Matters to a Vote of Security Holders
 
 None
 
 Item
5.   Other information
  None
 
 Item
6.   Exhibits and Reports on Form 8-K
  Reports on Form
8-K
  NONE
 
 Exhibits
  Medical
International Technology includes herewith the following exhibits.
  31.1           Certification
of Principal Executive Officer pursuant to Rule
13a-14(a)/15(d)-14(a)).
  31.2           Certification
of Principal Accounting Officer pursuant to (Rule
13a-14(a)/15(d)-14(a)).
 
 32.1           Certification
of Principal Executive Officer pursuant to (18U.S.C.
1350)
 
 32.2           Certification
of Principal Accounting Officer pursuant to (18U.S.C.
1350)
   -16-
  
 SIGNATURES
 
 In
accordance with the requirements of the Exchange Act, the registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.
 
 Medical
International Technology, Inc.
 Registrant
 
 Date: February 17,
2009                                                
By:\s\Karim Menassa,
President
 Karim Menassa, President and Principal Executive Officer
 
 Date: February 17,
2009                                                By:\s\Michel Bayouk,
Secretary
 Michel Bayouk, Secretary and Principal Accounting Officer


-17-